Inclusion Criteria:

The Patient may only be included in the study if ALL of the following statements are
fulfilled:

1. Male or female patient diagnosed with metastatic non hematological cancer, with up to
4 brain metastases of which at least one has a minimal diameter of 1.5cm , as
assessed by MRI (utilized for SRS planning) and is scheduled for SRS. These
metastases will be defined as target lesions.

2. Patient is ≥ 18 years of age at the time of signature of the informed consent form.

3. Fully conscious patient who has been given written and verbal information, and has
then provided an informed consent.

4. Patient who is able to cooperate with the studies requirements to lie still during
PET/CT imaging scans, which may last for up to 3 hours.

5. ECOG performance status of 0, 1 or 2 at the time of enrollment.

6. Patient with life expectancy ≥ 12 weeks.

7. Adequate renal function and adequate hepatic function as assessed by standard
laboratory criteria and defined as:

1. Creatinine clearance ≥ 60 ml/min/1.73m2according to Cockroft & Gault Formula

2. Total bilirubin ≤ 1.5 times the ULN

3. Aspargine aminotransferase (AST), alanine aminotransferase (ALT) ≤ 3 times the
ULN in patients without liver metastases; ≤ 5 times the ULN in patients with
liver metastases

8. Serum calcium levels, adjusted to albumin level, within normal limits.

9. For a female patient, pregnancy or breast-feeding are restricted. Woman of child
bearing potential must have a negative serum pregnancy test at screening.

Exclusion Criteria:

If any apply, the patient must not be included in the study:

1. Unstable medical condition, such as severe ischemic heart disease, liver disease or
pulmonary disease, which may risk the patient during the study, as judged by the
investigator.

2. Any indication of imminent brain herniation

3. Any known psychiatric disorder other than mild depression or anxiety.

4. Known allergy to Gadolinium

5. Other condition that might jeopardize the safety of the patient or the evaluation of
the study results, as judged by the investigator.

6. Treatment with any non-marketed investigational drug within 30 days prior to
administration of [18F]-ML-10

7. Patient who received Whole Brain Radiation Therapy (WBRT) within 6 months prior
screening and/or planned to receive WBRT 8 weeks post SRS

8. Patient receiving concurrent treatment with temozolamide or planned to receive
temozolamide within 8 weeks post SRS

9. Woman of child-bearing potential who is not using an adequate and medically
acceptable contraceptive method. Men who do not agree to use effective contraception
during the study and for a period of 60 days following the last administration of
[18F]-ML-10.